Renal cell carcinoma treated by vaccines for active
specific immunotherapy: correlation of survival with skin
testing by autologous tumor cells.
McCune CS, O'Donnell RW, Marquis DM, Sahasrabudhe DM.
University of Rochester Cancer Center, University of
Rochester School of Medicine and Dentistry, New York
14642. Abstract
Eighteen patients with metastatic renal cell carcinoma,
who were treated by vaccines for active specific
immunotherapy, also completed skin testing with autologous
tumor cells, both prior to and following vaccine
treatment. All patients have now been followed for more
than 5 years. Ten patients who remained skin-test-negative
following treatment had no clinical responses, and all had
expired by 22 months. Eight patients became
skin-test-positive; three of these had clinical
regressions and three remain alive after more than 69
months. The survival times of the skin-test-positive group
were significantly superior to those of the
skin-test-negative group. The results suggest that skin
testing with autologous tumor cells may accurately
identify those patients who have acquired antigen-specific
cell-mediated antitumor immunity.
http://www.ncbi.nlm.nih.gov/pubmed/2289200
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment